Bausch Health vs BYD: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bausch Health and BYD side by side

1. 1959Bausch Health

   Milan Panic founds ICN Pharmaceuticals

   Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.

2. 1994Bausch Health

   Biovail Corporation International formed in Canada

   On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.

3. 1995BYD

   BYD founded in Shenzhen

   Wang Chuanfu and his cousin Lu Xiangyang start BYD in Shenzhen with about 20 employees, making rechargeable batteries for mobile phones.

4. 2000BYD

   Becomes a leading NiCd battery maker

   BYD becomes one of the world's largest makers of nickel-cadmium batteries, supplying major electronics brands.

5. 2002BYD

   Hong Kong listing

   BYD lists its H shares on the Hong Kong Stock Exchange under stock code 1211.

6. 2003Bausch Health

   ICN renames itself Valeant Pharmaceuticals

   ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.

7. 2003BYD

   Buys Qinchuan and enters the car business

   BYD acquires a controlling stake in Xi'an Qinchuan Automobile for about $37.4 million (CN¥269 million), gaining a car production licence and factory.

8. 2008Bausch Health

   J. Michael Pearson becomes chief executive

   Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.

9. 2008BYD

   Berkshire Hathaway takes about 10%

   Berkshire Hathaway's MidAmerican Energy invests $232 million for about 10% of BYD, giving the company international credibility.

10. 2008BYD

    Launches the F3DM plug-in hybrid

    BYD launches the F3DM, the world's first mass-produced plug-in hybrid car, two years before the Chevrolet Volt.

11. 2010Bausch Health

    Biovail and Valeant complete their merger

    The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.

12. 2010BYD

    Denza joint venture with Daimler

    BYD and Daimler set up Denza as a 50:50 joint venture to build premium electric cars in China.

13. 2011Bausch Health

    Ortho Dermatologics bought from Johnson and Johnson

    Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.

14. 2011BYD

    Launches the e6 and lists in Shenzhen

    BYD launches the e6 electric crossover, first used as a taxi in Shenzhen, and lists A shares on the Shenzhen Stock Exchange (002594).

15. 2013Bausch Health

    Bausch + Lomb acquired for $8.7 billion

    Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.

16. 2015Bausch Health

    Salix acquisition closes at about $11.1 billion

    Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.

17. 2015Bausch Health

    Drug pricing and Philidor scandal breaks

    Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.

18. 2016Bausch Health

    Joseph Papa replaces Pearson as chief executive

    Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.

19. 2017Bausch Health

    Skincare brands and Dendreon sold to cut debt

    Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.

20. 2018Bausch Health

    Company renamed Bausch Health Companies Inc.

    The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.

21. 2020Bausch Health

    SEC settlement closes the Philidor accounting case

    On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.

22. 2020BYD

    Launches the Blade Battery

    BYD introduces the Blade Battery, an LFP cell-to-pack design that passes the nail penetration test without fire.

23. 2022Bausch Health

    Bausch + Lomb listed on the NYSE and TSX

    Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.

24. 2022BYD

    Ends combustion-only car production

    In March 2022 BYD stops making combustion-only passenger cars and focuses entirely on battery EVs and plug-in hybrids.

25. 2023BYD

    Passes Tesla in quarterly BEV sales

    BYD sells 3.02 million new energy vehicles in 2023, and its 526,409 battery EVs in the fourth quarter top Tesla's 484,507 for the first time in a quarter.

26. 2024BYD

    Takes full ownership of Denza

    Mercedes-Benz sells its last 10% of Denza in July 2024, leaving BYD as the sole shareholder of its premium brand.

27. 2025Bausch Health

    DURECT acquired and record annual revenue reported

    Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…

28. 2025BYD

    Berkshire Hathaway exits

    Berkshire Hathaway confirms in September 2025 that it has sold its entire BYD stake, ending a 17-year investment.

29. 2025BYD

    Becomes the world's top battery EV seller

    BYD sells 2.26 million battery EVs in 2025 against Tesla's 1.64 million, and 4.6 million new energy vehicles in total.

30. 2026Bausch Health

    RED-C trials miss endpoints and trigger a $1.4 billion charge

    In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.

31. 2026Bausch Health

    Second-quarter 2026 revenue of $2.85 billion and raised guidance

    Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.

32. 2026BYD

    Unveils Blade Battery 2.0 and FLASH charging

    On March 5, 2026 BYD unveils the second-generation Blade Battery, which charges from 10% to 70% in about five minutes, and plans 20,000 FLASH charging stations in China by the end of 2026.

33. 2026BYD

    Overseas revenue passes China

    In the first half of 2026 BYD's overseas revenue of ~$25.2 billion (CN¥181.3 billion) exceeds revenue from China for the first time, even as group revenue falls 7.1% to ~$47.9 billion (CN¥344.8 billion).

Acquisitions

Questions about Bausch Health vs BYD